Purchasing over $3,500? Contact us for further discounts. Over 250,000+ Products Available and Growing!

Rapid Test Kit, SARS-CoV-2 / Influenza A + B Antigen Detection, Rapid Chromatographic Digital Immunoassay, Test Device Format, For use with the BD Veritor Plus Analyzer running Firmware version 5.50 or late, sold as 30 Tests/Kit by BD 256088

We only sell to businesses, clinics, government facilities, individuals may contact us by email - info@go3a.com

Item#: BD-256088-KT

$828.75
Item(s) Total: $828.75
  • PRODUCT DETAILS
  • GOT QUESTIONS
  • RECENTLY VIEWED



Price shown is sold as Per Kit
  • Product Details
  • Dealer# 1192774
    Manufacturer # 256088
    Brand BD Veritor™ System
    Manufacturer BD
    Country of Origin Unknown
    Application Rapid Test Kit
    Contents 1 (30) Single Use Test Devices, (30) Single Use Reaction Tubes with 400 µL Reagent, (30) Sterile Single Use Sampling Swabs, 1 Positive SARS-CoV-2 Control Swab, 1 Positive Flu A Control Swab, 1 Positive Flu B Control Swab, (3) Paperboard Tube Stands, IFU, Quick Ref Card, and Nasal Sampling Guide
    For Use With For use with the BD Veritor™ Plus Analyzer running Firmware version 5.50 or late
    HCPCS U0003
    Number of Tests 30 Tests
    Reading Type Machine Read
    Sample Type Direct Anterior Nasal Swab Sample
    Test Format Test Device Format
    Test Method Rapid Chromatographic Digital Immunoassay
    Test Name SARS-CoV-2 / Influenza A + B
    Test Type Antigen Detection
    Time to Results 15 Minute Results
    UNSPSC Code 41116020

    Features

    • Shipments expected to begin around Sept 1, 2021 - Product ships with minimum 30 days dating
    • BD Triplex assay requires Veritor™ System firmware version 5.5 or greater; firmware version info is displayed on screen when turning on the analyzer or on the orange sticker if it is attached to the analyzer
    • BD Veritor System for Rapid Detection of SARS-CoV-2 and Flu A+B is For use under an Emergency Use Authorization only: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2thorized for use at the Point of Care (POC), i.e., i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
    • This test is authorized for use at the Point of Care (POC), i.e., i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditationtories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests
    • Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high, or waived complexity tests
    • The test is intended to be used with direct nasal swabs and is not validated for use with swabs in viral transport media
    • Kit configured for testing anterior nasal swab samples freshly collected, processed, and dispensed directly onto assay test device
    • Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status
    • Positive results do not rule out bacterial infection or co-infection with other viruses
    • Laboratories within the United States and its territories are required to report all SARS-CoV-2 results to the appropriate public health authorities
    • Negative results should be treated as presumptive, do not rule out either Influenza or SARS-CoV-2, and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions
    • Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with one of these infections
    • Negative results for SARS-CoV-2 should be confirmed with a molecular assay, if necessary, for patient management
    • The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for use in point of care settings by trained healthcare professionals or other users specifically instructed in the use of BD Veritor Systems and proper infection control procedures
    • Time to result: 15 minutes, test device can be read at 15 minutes but no later than 20 minute
    • Materials Required but not provided: BD Veritor™ Plus Analyzer running firmware v5.50 or later (Cat. No. 256066)
    • This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens
    We are here to help!
    Type your questions into the comment area below.
    For longer messages email us at: info@go3a.com
    • The BEST WAY to contact is by EMAIL - Use our "Contact Us" page, if you need immediate response, write URGENT on the subject line.
    • Emails are monitored 9 am - 4 pm, Mon-Fri, except Holidays, California Time.
    • Can't find the Exact Size? Contact us ( use "contact us" page) and we will get you the info.
    • Need it Yesterday? we have options for 2-3 days, 4-5 days use the check out page shipping options. Take note: the clock begins the day after the order and excludes week-ends and Holidays.
    • Can't Find the Exact Item but you found the Manufacturer? Send us the Info, and we will locate it for you.
    • Need a Quote? Please email us, be accurate with part#, description and quantities.
    • Overseas Customers? Contact us first before making your purchase.